Why Eli Lilly (LLY) rose 3.73%
Eli Lilly (LLY) rose 3.73% on November 9, 2026 — Foundayo trial data cuts apnea index, aids weight and CV.
What happened
Eli Lilly reported that Foundayo significantly reduced apnea-hypopnea index and improved weight and cardiovascular risk factors at 52 weeks. The stock rose 3.7% on the data.
Why it moved
Stronger results across several endpoints at once widen the commercial case for Foundayo beyond obesity into sleep apnea. Investors pay up for drugs that show multiple benefits, which expands the expected revenue pool.
Why it matters
Lilly sits in Healthcare and Biotech, where obesity and cardiometabolic drugs are among the largest new markets. A broader efficacy profile strengthens Lilly's position in that franchise.
What would break the thesis
Safety signals or a final readout that softens the headline metrics would undercut the rerating. Watch the full data package and regulatory filings for any side effects.